Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening A. CaldarellaD. PulitiE. Paci Original Paper 09 September 2012 Pages: 181 - 185
Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy Vesna BišofAntonija JakovčevićSlavko Gašparov Original Paper 26 September 2012 Pages: 187 - 194
Plasma human neutrophil proteins-1, -2, and -3 levels in patients with bladder cancer Mustafa GunesIlhan GecitMehmet Aslan Original Paper 26 September 2012 Pages: 195 - 199
KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines Isabelle MessnerGiuseppe CadedduKarl-Ludwig Schaefer Original Paper 27 September 2012 Pages: 201 - 209
A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy Qin MaoYu ZhangYou Lu Original Paper 30 September 2012 Pages: 211 - 222
Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer Haiyan SiXiaoming SunChengjin Hu Original Paper Open access 30 September 2012 Pages: 223 - 229
A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk Jun ChenReng-Yun LiuHong-Tao Zhang Original Paper 02 October 2012 Pages: 231 - 242
Is helical tomotherapy accurate and safe enough for spine stereotactic body radiotherapy? Yoonsun ChungHong In YoonWoong Sub Koom Original Paper 02 October 2012 Pages: 243 - 248
A nine-gene signature predicting clinical outcome in cutaneous melanoma G. BrunnerM. ReitzJ. Atzpodien Original Paper 09 October 2012 Pages: 249 - 258
Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancer Martin KochMichael Wiese Original Paper 09 October 2012 Pages: 259 - 267
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice Domenico AngelucciNicola TinariClara Natoli Original Paper Open access 10 October 2012 Pages: 269 - 280
Neonatal suprarenal mass: differential diagnosis and treatment Wei YaoKai LiLian Chen Original Paper 11 October 2012 Pages: 281 - 286
Overexpression of macrophage migration inhibitory factor in adenoid cystic carcinoma: correlation with enhanced metastatic potential Hui LiuGang ChenYi-Fang Zhao Original Paper 12 October 2012 Pages: 287 - 295
l-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients’ survival with stomach adenocarcinomas Dimitra FlorouIordanis N. PapadopoulosAndreas Scorilas Original Paper 12 October 2012 Pages: 297 - 306
Prognostic value and differences of the sixth and seventh editions of the UICC/AJCC staging systems in nasopharyngeal carcinoma Rui SunHui-Zhi QiuHao-Yuan Mo Original Paper 16 October 2012 Pages: 307 - 314
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb Debra T. ChaoMian SuPatricia A. Culp Original Paper Open access 17 October 2012 Pages: 315 - 325
New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma Ilknur KozanogluMelis Kartal YandimYusuf Baran Original Paper 19 October 2012 Pages: 327 - 335
Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval Deniz GencerSalah-Eddin Al-BatranRalf-Dieter Hofheinz Original Paper 19 October 2012 Pages: 337 - 345
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary Dirk BauerschlagKaren BräutigamIvo Meinhold-Heerlein Original Paper 23 October 2012 Pages: 347 - 355